) are found only in organisms of the animal kingdom and share several structural and enzymatic features. The presence of serine/arginine (S/R) dipeptide repeats in their C-terminal tail suggests that these enzymes belong to the SR protein family involved in the regulation of gene expression. The function of this group of cyclophilins is currently unknown. However, their C-terminal tails contain a highly conserved polypeptide signature segment (the moca domain), which may well be involved in the functional regulation of these proteins. We report here the identification of five Cdc2-type phosphorylation sites gathered in and around the moca domain of SRcyp, a human cyclophilin belonging to the Moca family. The segment of SRcyp containing the identified sites is specifically phosphorylated in mitotic cells. This mitosis-specific phosphorylation was inhibited by treatment of the cells with roscovitine, a specific inhibitor of cyclin-dependent kinases, suggesting that the unknown activity of the moca domain of SRcyp requires mitotic regulation by the Cdc2-cyclin B kinase complex. The Cdc2-cyclin B complex was found to phosphorylate four of the five identified phosphorylation sites in vitro, providing further support for this possibility. Like many factors stored in nuclear speckles and involved in the regulation of gene expression, this nuclear cyclophilin displays a predominantly diffuse cytoplasmic distribution at the onset of mitosis. Only in late telophase is SRcyp recruited to the newly formed nuclei. The transit of SRcyp through mitotic interchromatin granule clusters, before re-entering the nucleus, suggests that the timing of the appearance of this cyclophilin in the telophasic nuclei is tightly coordinated with post-mitotic events. Human SRcyp is the first cell cycle-regulated cyclophilin to be described.
enzyme families (FK506-binding proteins and parvulins; for reviews see Refs. 2 and 3). The first cyclophilin to be isolated was the cellular receptor for the immunosuppressant drug cyclosporin A (CsA). Other members of this family have since been identified in various cell compartments. Their functions are poorly understood but have been linked to cellular processes, such as protein folding (4) , trafficking (5) , chaperone activity (6) , oxidative stress response (7), functional arrangement of components within receptor complexes (8) , and apoptosis (9) . Recent studies have shown that cyclophilins may also be involved in nuclear events such as gene transcription and mRNA splicing. For example, the nuclear cyclophilin Cyp33, which harbors an RNA-binding motif (RRM (10) ) binds to and modulates the gene regulatory function of the human myeloid/ lymphoid leukemia (MLL/HRX/HTRX/All1) protein (11) . Another cyclophilin, Snucyp-20, is a specific component of the human U4/U6 small nuclear-ribonucleoprotein particle (12) and is involved in the nuclear splicing of pre-mRNA (13) .
The Moca family of nuclear cyclophilins, which we described recently (1) , may also be involved in the regulation of gene expression in multicellular organisms of the animal kingdom. The Moca family includes Moca-cyp, isolated from Drosophila melanogaster (1) ; matrin/SRcyp and NK-TR, isolated from humans and rodents (14 -17) ; cyp1, isolated from the parasite Brugia malayi (18) ; and cyp8 and cyp9, isolated from Caenorhabditis elegans (19) . All these proteins carry a highly conserved N-terminal PPIase domain followed by a long, divergent Cterminal tail. The members of this subfamily have much lower levels of PPIase activity than the prototypical cyclophilin, Cyp18, possibly reflecting specific substrate requirements. Indeed, the D. melanogaster Moca-cyp and B. malayi cyp1 enzymes have been shown to display a preference for a hydrophobic amino acid immediately N-terminal to the proline residue (1, 20) . Inhibition of the PPIase activity of the members of Moca family requires much higher concentrations of CsA apparently due to two amino acid substitutions in the catalytic domain. In addition to the structural and enzymatic features characterizing their PPIase domains, members of the Moca family have several structural characteristics in common in their C-terminal tails (1) . All carry multiple nuclear localization signals, and the presence of SR and RS dipeptide repeats suggests that these proteins belong to the family of serine/arginine (SR)-rich nuclear phosphoproteins involved in the splicing and processing of mRNA (21, 22) . Finally, a highly conserved polypeptide segment (the "moca" domain) within the C-terminal tail is the signature of Moca family members. We speculate that the conservation of this domain reflects a specific regulatory func-tion required for the unknown activity of this subfamily of cyclophilins (1) .
We report here the cell cycle regulation of the nuclear cyclophilin SRcyp 2 (14, 15) , a human protein belonging to the Moca family. The presence of five Cdc2-type phosphorylation sites gathered in and around the moca domain of SRcyp prompted us to investigate its phosphorylation during the cell cycle. In vitro and in vivo experiments showed that the moca domain of this cyclophilin was specifically phosphorylated during mitosis and that the master mitotic cyclin-dependent kinase, the Cdc2-cyclin B complex, was probably responsible for this phosphorylation. We also observed, in indirect immunofluorescence experiments, that the cellular location of SRcyp changed during the course of mitosis. SRcyp passed through cytoplasmic structures called mitotic interchromatin clusters (MIGs) (23) before entering the newly formed nuclei of the late telophasic cell. These properties of SRcyp suggest that this protein may be involved in the regulation of gene expression in post-mitotic cells.
EXPERIMENTAL PROCEDURES

Plasmids and Recombinant Proteins-We cloned the SRcyp cDNA as follows. Poly(A)
ϩ mRNA was extracted and purified (mRNA purification kit, Amersham Biosciences) from human U2OS cells (ATCC number, HTB-9624), synchronized at the S phase of the cell cycle (see below). The resulting RNA was used for reverse transcription (SMART RACE cDNA amplification kit; Clontech), and a 2267-bp fragment corresponding to the full-length open reading frame of the human SRcyp gene (nucleotides 153-2420 of the published sequence (15)) was amplified by PCR using the specific primers 5Ј-(XbaI)-GAGCCATGGGAATAAAGG-3Ј and 5Ј-(BamHI)-TCCGCTTTTGTCT-TCATCTG-3Ј and inserted into the pGEM-T/Easy vector (pGEM-T Easy kit, Promega). The resulting recombinant plasmid, pGEM-T/ SRcyp, was completely sequenced.
For in vivo expression experiments, pGEM-T/SRcyp was digested with XbaI and BamHI, and the 2267-bp fragment was released, purified, and ligated between the corresponding cloning sites in p3xFLAG-CMV-14 (Sigma) to generate the recombinant plasmid pCMV-SRcyp.
The recombinant plasmid pCMV-SRcypdelmoca, harboring an internal deletion in the moca domain of the SRcyp cDNA (between nucleotides 1133 and 1252), was derived from pCMV-SRcyp as follows. We used pCMV-SRcyp as a template for the PCR amplification of two fragments of SRcyp: 5Ј-fragment, nucleotides 153-1133, and 3Ј-fragment, nucleotides 1252-2420, located 5Ј and 3Ј of the segment to be deleted. The 5Ј-fragment was amplified with a vector-specific primer (5Ј-CGGCCGCGAATTCATCGATA-3Ј) containing an EcoRI site and a gene-specific primer (5Ј-CTAAAAGTCGTCTCTGGTATG-3Ј) supplemented with an SacII site. The 3Ј-fragment was amplified with a gene-specific primer (5Ј-GATGCAGAGAGCTCAAAGAA-3Ј) flanked by an SacII site and a vector-specific primer (5Ј-CCGTCATGGTCTTTG-TAGTC-3Ј). The amplified fragments were digested with EcoRIϩSacII and with SacIIϩBamHI, respectively, and were then coligated into p3xFLAG-CMV-14 digested with EcoRI and BamHI.
The recombinant plasmid pCMV-CAD, containing the moca domain sequence of the SRcyp cDNA, was also derived as follows. We used pCMV-SRcyp as a template for PCR amplification of the CAD fragment of the SRcyp cDNA (nucleotides 916 -1412 of the published sequence), using the primers 5Ј-(EcoRI)-ATGGGGAGTGCATCTAGTGAGAG-3Ј and 5Ј-(BamHI)-TCTGTTTGGACTCTCAGATAC-3Ј. The amplified CAD fragment was digested with EcoRI and BamHI and ligated into the corresponding cloning sites of p3xFLAG-CMV-14 (Sigma) to generate the recombinant plasmid pCMV-CAD.
To obtain the recombinant plasmids pGEX-CBC, pGEX-CBD, pGEX-CAC, and pGEX-CAD, overlapping fragments of the human SRcyp cDNA corresponding to segments B-C, B-D, A-C, and A-D (nucleotides 1105-1315, 1105-1410, 916 -1315, and 916 -1410 of the published cDNA sequence (15) ) were amplified by PCR (Advantage 2 PCR kit, Clontech) using gene-specific primers as follows: A, 5Ј-(EcoRI)-GAGT-GCATCTAGTGAGAG-3Ј; B, 5Ј-(EcoRI)-GCCTGCTTCATACCAGA-GAC-3Ј; C, 5Ј-(BamHI)-ACTCTTATCCCCCTTGATCC-3Ј; and D, 5Ј-(BamHI)-CTGTTTGGACTCTCAGATAC-3Ј. The amplified fragments were digested with EcoRI and BamHI restriction and ligated between the corresponding cloning sites of pGEX-2TKL.
The plasmid construction procedures resulted in the loss of Cdc2 phosphorylation site P5 (ESPNRK) from pGEX-CAD and pGEX-CBD (nucleotides 916 -1410 and 1105-1410, respectively, of the published sequence). This site was lost because the terminal residue at the 3Ј end of both insert fragments was an asparagine (Asn-417), which is part of the consensus Cdc2 phosphorylation site P5 (ESPNRK). This residue was immediately followed by a serine residue translated from a linker sequence, replacing the arginine (Arg-418) present in the original P5 site. We used a site-directed mutagenesis kit (QuickChange Site-directed Mutagenesis kit, Stratagene) and the primers 5Ј-GAGTCCAAA-CAGAGGGATCCAATTC-3Ј and 5Ј-GAATTGGATCCCTCTGTTTG-GACTC-3Ј to replace the serine by an arginine in both plasmids, giving pGEX-CADn and pGEX-CBDn.
We generated pGEX-CAB (SRcyp nucleotides 916 -1144 of the published sequence (15) ) from pGEX-CAD. Briefly, pGEX-CAD was digested with BglII (which cuts into the CAD fragment) and BamHI (3Ј-cloning site in the vector). The resulting 5.2-kb fragment corresponding to the vector and the 5Ј portion of CAD was religated and used to transform bacteria. The resulting plasmid was named pGEX-CAB.
All these recombinant plasmids were used for GST fusion protein production (24) . GST fusion proteins were produced in bacteria and recovered on glutathione-Sepharose 4B beads (Amersham Biosciences), from which they were eluted for 15 min at 4°C with 20 mM reduced glutathione (Sigma) in 120 mM NaCl and 100 mM Tris, pH 8. After quantification (Bio-Rad protein assay), eluted proteins were used as substrates for the in vitro kinase assay.
Cell Culture, Transfection, and Synchronization-U2OS cells were cultured at 37°C in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum (Sigma) and transfected using an Invitrogen calcium phosphate transfection kit and procedures. Clones of transfected U2OS cells stably expressing pCMV-SRcyp, pCMV-Srcypdelmoca, and pCMV-CAD were established by cotransfection with the plasmids described above and the pPuro plasmid (Clontech) followed by selection in the presence of 0.5 g/ml of puromycin (Clontech) and 0.5 mg/ml of geneticin (Invitrogen).
For cell cycle synchronization, cells were seeded at 1.5 ϫ 10 6 cells per plate and incubated for 24 h. We then added 0.5 mM hydroxyurea (Sigma) to the medium and incubated the plates for a further 16 h. The cells were washed twice with drug-free medium and then incubated for 4 h in the presence of drug-free medium, for the collection of S phase cells, or for 8 h, after which nocodazole (0.1 g/ml; Sigma) was added. Loosely attached mitotic cells were collected after 12 h of incubation with nocodazole. Nocodazole-treated cells were washed twice and replated in drug-free medium and incubated for 2 h at 37°C to obtain cells in the G 1 phase of the cycle. Where indicated, mitotic cells obtained by nocodazole treatment were incubated in the presence of 100 M roscovitine (Calbiochem) for 1-3 h at 37°C.
Samples corresponding to synchronization at various stages were fixed in 40% ethanol and stained with 46 g/ml propidium iodide in the presence of 5 g/ml DNase-free RNase (Roche Applied Science). Cell cycle profiles were determined by flow cytometry with a Coulter XL Analyzer, and data were analyzed with Phoenix Flow Systems Inc., Multicycle AV software.
Antibodies-We used the following antibodies: anti-FLAG (mAb M2; Sigma), anti-cyclin B1 (mAb C23420; Transduction Laboratories), antiCdc2(p34) (mAb sc-54; Santa Cruz Biotechnology), anti-GAPDH (mAb 374; Chemicon International), 3C5 mAb (provided by B. Turner), and anti-lamin A/C rabbit polyclonal serum (provided by B. Buendia).
Cell Extract Preparation, Immunoprecipitation, and Western Blot Analysis-For extract preparation, cells were harvested, washed three times with ice-cold phosphate-buffered saline (8.1 mM Na 2 HPO 4 , 135 mM NaCl, 1.5 mM KH 2 PO 4 , 2.7 mM KCl), and lysed by incubation for 20 min at 4°C in one of the following buffers: Net.N-300 (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 0.1% Igepal), NetN-150 (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Igepal), or RIPA 1ϫ (150 mM NaCl, 50 mM Tris, pH 8.0, 1% Igepal, 0.1% SDS, 0.5% sodium deoxycholate), supplemented with protease inhibitors (EDTA-free protease inhibitor tablets (Roche Applied Science), aprotinin (Sigma), leupeptin (Roche Applied Science), pepstatin (Roche Applied Science) (20 g/l each), and 1 mM phenylmethylsulfonyl fluoride (Sigma)) and phosphatase inhibitors (50 mM NaF and 2 mM Na 3 VO 4 ). The lysate was centrifuged for 10 min at 13,000 ϫ g to eliminate cell debris. The proteins present in the supernatant were quantified (Bio-Rad protein assay) and resolved directly by SDS-PAGE after boiling in 1ϫ SB (2% SDS, 10% glycerol, 62.5 mM Tris-HCl, pH 6.8, 100 mM dithiothreitol) or subjected to immuno-precipitation and/or Western blot analysis.
For immunoprecipitation, we coated protein G-Sepharose CL-4B beads (40 l of a 50% slurry, Amersham Biosciences) with the antibodies indicated, by incubating for 2 h at 4°C in 600 l of binding buffer (20 mM Tris-HCl, pH 8.0, 120 mM NaCl, 1 mM EDTA, 0.5% Igepal). The antibody-coated beads were washed three times in binding buffer and incubated for 2 h at 4°C with 500 g of cell lysate, in a final volume of 600 l. The beads were washed four times with lysis buffer and were then used for the in vitro kinase assay.
For Western blot analysis, SDS-PAGE-separated proteins were transferred onto nitrocellulose membrane (Schleicher & Schuell), using Towbin buffer (25) and a semi-dry electrotransfer device (Bio-Rad). The membranes were blocked by incubating with 5% nonfat milk powder in TBST buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween 20) supplemented with 0.1% sodium azide for 2 h and then for a further 3 h at room temperature with the specified primary antibody diluted in the same incubation mixture. The membrane was washed four times in TBST buffer and incubated with a horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences), and antibody binding was detected with the ECLϩ chemiluminescence detection kit (Amersham Biosciences).
Protein Phosphatase Treatment-We used 400 units of protein phosphatase (New England Biolabs) per 100 g of cell extract and 100 l of reaction buffer. The reaction buffer was 150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 0.05% Igepal, 0.1 mM Na 2 EDTA, 5 mM dithiothreitol, 0.01% Brij 35, 2 mM MnCl 2 . The reaction mixture was incubated for 2 min at 30°C. The cell extract was then added and the mixture incubated for 30 min at 30°C. We added an equal volume of 1ϫ SB to the reaction mixture, and the sample was then boiled and analyzed by Western blotting. Where indicated, the phosphatase treatment was carried out in the presence of a mixture of phosphatase inhibitors: 10 mM NaF, 10 mM Na 3 VO 4 , 10 mM EDTA, and 100 nM microcystin.
In Vitro Kinase Assay-The Cdc2-cyclin B kinase complex was immunoprecipitated from 500 g of mitotic U2OS cell extract using an anti-cyclin B1 (mAb C23420, Transduction Laboratories) or an antiCdc2(p34) (mAb sc-54, Santa Cruz Biotechnology) mAb bound to protein G-Sepharose beads (Amersham Biosciences). The bound kinase complex was washed three times with lysis buffer and once with the kinase buffer (25 mM Hepes, pH 7.4, 25 mM MgCl 2 , 25 mM ␤-glycerophosphate, 2 mM dithiothreitol, and 0.1 mM Na 3 VO 4 ). The beads were then incubated for 30 min at 30°C in 50 l of kinase buffer supplemented with 50 M ATP, 5 Ci of [␥-32 P]ATP, and the substrate (histone H1 (1 g) or the indicated amount of GST fusion protein). The reaction was stopped by boiling the sample with 50 l of 1ϫ SB. Proteins were resolved by SDS-PAGE and transferred to a nitrocellulose membrane (Schleicher & Schuell). This filter was first placed against x-ray film and was then probed with an anti-Cdc2 mAb (1:1000 dilution).
Where indicated, peptides were used as substrates for the in vitro kinase assay. For this purpose, 14-mer peptides, each encompassing one of the Cdc2 phosphorylation sites identified in SRcyp, were synthesized, purified, subjected to mass spectrometry to check their sequences, and then biotinylated as described by Lobl et al. (26) . For the in vitro phosphorylation assay, each peptide, used at a final concentration of 10 M, was incubated with Cdc2 kinase buffer (75 mM Tris-HCl, pH 7.5, 15 mM MgCl 2 , 1.5 mM EGTA, 3 mM dithiothreitol, 0.015% Brij 35) supplemented with 6 Ci of [␥-
33 P]ATP, 500 M unlabeled ATP, and 0.04 units of recombinant Cdc2-cyclin B complex (Upstate Biotechnology, Inc.) in a final volume of 11 l. The reaction mixture was incubated for 60 min at 30°C. The reaction was stopped by adding 150 l of ATP (1 mM). The mixture was transferred to a streptavidin-coated scintillation plate, which was incubated for 20 min, and washed three times, and the amount of bound 33 P-labeled biotinylated peptide was determined with a Wallac Microbeta Jet 1450 scintillation counter. As a control, each peptide was incubated without the kinase. For each sample, the background value was subtracted from the radioactivity count obtained in the presence of kinase.
Indirect Immunofluorescence Analysis-Stably transfected cells were arrested in prometaphase by nocodazole treatment (65 ng/ml) for 14 -16 h. Loosely attached mitotic cells were harvested, washed twice with drug-free medium, and seeded onto poly-L-lysine-coated (Sigma) chamber slides (Lab-Tek). Various times after the removal of nocodazole, cells were fixed with 3% paraformaldehyde and permeabilized with 0.1% Triton in phosphate-buffered saline at room temperature. FLAGtagged proteins were detected by incubation with an anti-FLAG mAb (M2, Sigma) (1:4000 dilution), followed by a fluorescein isothiocyanateconjugated goat anti-mouse antibody (Jackson ImmunoResearch). Where indicated, cells were costained with a polyclonal rabbit antilamin A/C serum (1:400 dilution), which was detected with a Texas Red-conjugated goat anti-rabbit antibody (Jackson ImmunoResearch). Costaining with the anti-FLAG (IgG1) and 3C5 (IgM) monoclonal antibodies was achieved by fixing nocodazole-treated cells in methanol for 5 min at Ϫ20°C and permeabilizing them by incubation with phosphate-buffered saline, 0.5% Triton, 2% normal goat serum for 15 min at room temperature. Following incubation with the anti-FLAG (1:4000 dilution) and 3C5 (1:50 dilution) antibodies, staining was detected by incubation with an fluorescein isothiocyanate-conjugated goat antimouse IgG (Jackson ImmunoResearch) and a tetramethylrhodamineconjugated goat anti-mouse IgM (Southern Biotechnology). We stained the DNA in the samples with 0.5 g/ml 4Ј,6-diamidino-2-phenylindole. Samples were then mounted using Vectashield H-1000 (Vector Laboratories) and observed by microscopy.
RESULTS
The Moca Domain of SRcyp Is Phosphorylated in a Cell
Cycle-dependent Manner-Analysis of the primary amino acid sequences of cyclophilins of the Moca family (1) has revealed several consensus phosphorylation sites for cyclin-dependent kinases. We investigated possible links between the cell cycle machinery and the moca domain of these cyclophilins (1) by checking that these Cdc2-type phosphorylation sites were present and conserved within the domain. Alignment of the moca domains of several of these cyclophilins (Fig. 1A) showed the presence of two potential Cdc2-type phosphorylation sites. The first consensus site (RTPSR, Fig. 1A , asterisk) is conserved in human, mouse, rat, and Drosophila but is absent from the cyclophilins identified in nematodes. The second phosphorylation site identified (ETPPH, Fig. 1A , asterisk) was atypical and was conserved in all the proteins studied.
The moca domain of the human SRcyp (14, 15) is flanked by three additional Cdc2-type phosphorylation sites that are not conserved in other members of the family (Fig. 1B) . Furthermore, a cyclin-binding motif (RXL) (27) (28) (29) within the moca domain and three KEN box motifs, initially described in cell cycle-regulated proteins (30) , were also identified. These observations led us to focus our attention on SRcyp and to study the phosphorylation of the moca domain of this cyclophilin by cyclindependent kinases during the course of the cell cycle.
As phosphorylation events may affect the electrophoretic mobility of proteins, Western blots were carried out to investigate possible cell cycle regulation of SRcyp phosphorylation. We obtained stably transfected clones of human U2OS cells overproducing a FLAG-tagged version of SRcyp. We synchronized these cells at various stages of the cell cycle, and we prepared protein extracts, which we then analyzed by Western blotting with an anti-FLAG mAb. The SRcyp-FLAG protein extracted from mitotic cells displayed an electrophoretic mobility shift with respect to the protein extracted from the other stages (data not shown). As the C-terminal tail of SRcyp contains multiple phosphorylation sites for many different kinases (including CaMII, CKI, CKII, p70s6k, cAMP-dependent protein kinase, and protein kinase C; cbs.dk/htbin/pbase), we minimized the possible effects of these additional kinases by limiting our study to a fragment of SRcyp (fragment CAD, residues 254 -418 of the published sequence (15)) encompassing the moca domain, the five Cdc2-type phosphorylation sites, and the cyclin-binding motif (Fig. 1B) . We obtained stably transfected clones of human U2OS cells producing a FLAG-tagged version of the CAD fragment (CAD-FLAG), synchronized them at various stages of the cell cycle (see "Experimental Procedures"), and prepared protein extracts, which we then analyzed by Western blotting with an anti-FLAG mAb. The CAD-FLAG protein extracted from mitotic cells after nocodazole treatment clearly displayed an electrophoretic mobility shift with respect to the proteins extracted at other stages and from asynchronous growing cells (Fig. 2A, top panel) . Sample loading and cell synchronization efficiency were checked by Western blotting with an anti-GAPDH mAb (Fig. 2A, middle panel) and an anti-cyclin B1 mAb ( Fig. 2A, bottom panel) (31) , respectively. We then investigated whether the electrophoretic mobility shift of CAD-FLAG was due to cell cycle-regulated phosphorylation by treating extracts prepared from nocodazole-arrested cells with phosphatase before Western blotting (Fig. 2B, top panel) . The mobility shift was specifically lost in the presence of phosphatase, indicating that the slower migration of the CAD-FLAG extracted from mitotic cells resulted from phosphorylation events. We then investigated whether the Cdc2-cyclin B kinase complex, the major cyclin-dependent kinase in mitotic cells (32) , was involved in the specific phosphorylation of CAD-FLAG. The mitosis-specific electrophoretic mobility shift was reversed in nocodazole-treated cells incubated with roscovitine, an inhibitor of Cdk2 and Cdc2 (33) (Fig. 2C, top panel) , strongly suggesting that the Cdc2-cyclin B kinase complex was involved. We checked that roscovitine treatment was efficient by Western blot analysis of the samples with the MPM2 monoclonal antibody, which specifically recognizes mitosis-regulated phosphoepitopes (34) (Fig. 2C, bottom panel) .
The Moca Domain of SRcyp Is Phosphorylated in Vitro by the Cdc2-Cyclin B Kinase-To investigate the phosphorylation of the CAD fragment of SRcyp by the Cdc2-cyclin B kinase complex in vitro, we used mAbs directed against cyclin B (Fig. 3A) or Cdc2 (Fig. 3B) to immunoprecipitate endogenous active Cdc2-cyclin B kinase complex from mitotic U2OS cells obtained by nocodazole treatment (see "Experimental Procedures"). The kinase complexes were incubated in presence of [␥-
32 P]ATP and various GST fusion protein substrates carrying overlapping fragments of CAD (Fig. 3, A and B ; see "Experimental Procedures"). Histone H1 and GST protein alone were used as positive and negative control substrates, respectively. Immunoprecipitation was checked by Western blotting with an antiCdc2 antibody (Fig. 3, A and B, bottom panels) . As the cell extracts used for immunoprecipitation were prepared following nocodazole treatment and shake-off (more than 90% mitotic cells; data not shown), we thought that anti-cyclin B and antiCdc2 antibodies would essentially immunoprecipitate active Cdc2-cyclin B complexes, with similar in vitro phosphorylation profiles in each case. Indeed all GST fusion proteins were phosphorylated in vitro, and we observed no major difference in kinase activity profile between the two sets of immunoprecipitated complexes (Fig. 3, A and B) . We therefore concluded that Cdc2-cyclin B phosphorylated the Cdc2-type sites present in the CAD fragment. The GST-CAB fusion, which contains the P1 phosphorylation site, was a very poor substrate in both experiments (Fig. 3, A and B) . It therefore seems likely that the efficiency of the kinase depends on the sequence of each phosphorylation site.
We assessed the preference of the Cdc2-cyclin B kinase complex for each of the five sites identified in the CAD fragment (Fig. 1B) . Five peptides, each encompassing one site, were synthesized and used as substrates in an in vitro phosphorylation assay carried out with [␥- 33 P]ATP and a commercially available purified Cdc2-cyclin B complex (see "Experimental Procedures") (Fig. 4) . Our results confirmed that the kinase phosphorylated the various sites with different efficiencies. Peptide 2, which contained the P2 phosphorylation site, was the most efficiently phosphorylated substrate, followed by peptides 4 and 5. Peptide 3, which contained the atypical Cdc2 site P3, was also labeled but much less efficiently than peptides 2, 4, and 5. Finally, peptide 1 showed the lowest level of incorporation, close to background levels, confirming observations for the in vitro phosphorylation of GST fusion proteins (Fig. 3) .
Thus, we showed that the cyclin-dependent kinase complex Cdc2-cyclin B phosphorylated the CAD fragment of SRcyp in vitro. The preference of this kinase for the P2 site in the moca domain suggests that the cell cycle regulation machinery may specifically target the activity of the moca domain in mitotic cells.
SRcyp Enters the Nuclei of Telophasic Cells after Nuclear Membrane Formation-As our results suggested that the activity of the nuclear cyclophilin SRcyp could be regulated by Cdc2-cyclin B, we investigated whether the cellular distribution of this protein changed during the course of mitosis. A stably transfected clone of human U2OS cells producing a Cdk inhibitor roscovitine for 1 h (Rosco 1h) or 3 h (Rosco 3h). Protein extracts were then prepared from these cells and from asynchronously growing cells (AS) and analyzed by Western blotting with an anti-FLAG mAb (top panel), anti-GAPDH mAb (middle panel), and anti-MPM2 mAb (lower panel).
FIG. 2. Mitotic phosphorylation of the CAD fragment of SRcyp.
A, electrophoretic mobility shift of the CAD-FLAG protein extracted from mitotic cells. Protein extracts prepared from synchronized (S, M, and G 1 phases) or asynchronous (AS) cells of a transfected U2OS clone stably overproducing the recombinant CAD-FLAG protein were analyzed by Western blotting with an anti-FLAG mAb (top panel), anti-GAPDH mAb (middle panel), and anti-cyclin B mAb (lower panel). B, the electrophoretic mobility shift of the CAD-FLAG protein extracted from nocodazole-treated cells is sensitive to phosphatase treatment. Protein extract was prepared from mitotic cells obtained after nocodazole treatment as in A, incubated in presence or absence of phosphatase, using the experimental conditions described in the table at the bottom. Then samples were used for Western blotting with an anti-FLAG mAb (top panel) and anti-GAPDH mAb (middle panel). Coomassie Blue staining of the SDS-PAGE gel is also shown (lower panel). C, the mitotic phosphorylation of the CAD-FLAG protein is sensitive to roscovitine treatment. Cells of the transfectant U2OS clone stably overproducing the recombinant CAD-FLAG protein were treated with nocodazole and incubated in the presence of DMSO (MϩDMSO) or the
FIG. 3. The Cdc2-cyclin B complex phosphorylates the CAD fragment of SRcyp in vitro.
Cdc2-cyclin B complexes were immunoprecipitated (IP) from nocodazole-treated U2OS cells, using an anticyclin B mAb (A) or an anti-Cdc2 mAb (B). The immunoprecipitated kinase complex was then assayed, using GST-CAD or various GST fusion substrates corresponding to fragments of CAD. We used GST alone and histone H1 as negative and positive controls, respectively. Each immunoprecipitation was checked by Western blotting with an anti-Cdc2 mAb (bottom panels of A and B).
FLAG-tagged version of SRcyp (SRcyp-FLAG) was synchronized by nocodazole treatment and analyzed by indirect immunofluorescence (see "Experimental Procedures"). During prometaphase, which is characterized by a nuclear envelope breakdown and moving of the condensed chromosomes toward the metaphase plate, SRcyp-FLAG displayed predominantly diffuse cytoplasmic staining (Fig. 5A) . During metaphase, the protein was completely absent from the chromosomes, which were aligned at the metaphase plate (Fig. 5A) . At anaphase, when the chromosomes began to be pulled toward the poles, small and condensed stained structures were observed in addition to the diffuse pattern of SRcyp-FLAG staining (Fig. 5A) . The number and size of these cytoplasmic structures increased as cells progressed from anaphase to telophase (Fig. 5A) . When the daughter cells began to undergo cytokinesis, SRcyp-FLAG was found exclusively in the nucleus, with a speckled pattern in G 1 cells (Fig. 5A) .
We investigated whether the cytoplasmic SRcyp-positive structures were included in the nuclei of the telophasic cell before or after formation of the nuclear membrane by means of costaining experiments with the anti-FLAG mAb and a polyclonal anti-lamin A/C serum that specifically stains the nuclear envelope. We found that, in late telophase, the cytoplasmic SRcyp structures entered the nuclei after formation of the nuclear envelope (Fig. 5B) .
As the highly conserved moca domain is the signature of this very small group of cyclophilins, it probably has a key regulatory function. Our observations suggest that the unknown activity of this domain, at least in the context of SRcyp, requires a mitotic regulation.
The effect of the regulatory elements located in the moca domain of SRcyp was investigated by constructing a recombinant plasmid, pCMV-SRcypdelmoca, harboring an internal deletion covering the moca domain ( Fig. 1A ; see "Experimental Procedures"). We transiently transfected U2OS cells with the recombinant plasmid and analyzed the cellular distribution of the FLAG-tagged SRcyp-delmoca protein, and we found that, as for the wild-type protein, the deleted version of SRcyp was located in the nucleus, giving a speckled pattern of staining (data not shown). Thus, deletion of the moca domain did not affect the nuclear distribution of the protein during interphase. We subsequently obtained clones of stably transfected U2OS cells overproducing SRcyp-delmoca (see "Experimental Procedures"), which we compared with cells overproducing wild-type SRcyp. The cell cycle distribution of the clones was checked by fluorescence-activated cell sorter analysis; we compared two exponentially growing SRcyp-delmoca clones with two wildtype SRcyp and two controls clones obtained by transfecting U2OS cells with empty vector (data not shown). The cell cycle distribution of the wild-type SRcyp clones was similar to that of the controls transfected with the empty vector. By contrast, for the two clones overproducing the deleted protein, a fraction of the cell population had a sub-G 1 DNA content. The presence of sub-G 1 cells, indicative of apoptosis, suggested that the stable overproduction of SRcyp-delmoca might be contradictory with the long term in vitro proliferation of the established clones.
The SRcyp-delmoca overproducing cells were synchronized by nocodazole treatment and analyzed by indirect immunofluorescence assays with an anti-FLAG antibody (see "Experimental Procedures"). A larger proportion of SRcyp-delmoca clone cells than of cells overproducing wild-type SRcyp had lost the recombinant protein (even during early passages; data not shown), suggesting that SRcyp-delmoca has an inhibitory effect. We checked the cellular distribution of the deleted recombinant protein in mitotic cells stained with the anti-FLAG antibody. The cytoplasm of the prometaphasic cells overproducing SRcyp-delmoca displayed not only the diffuse staining observed with the wild-type protein but also large aggregates (Fig. 5C) . We also detected cells with condensed structures in the cytoplasm, between the anaphase and telophase stages, but these cells were extremely rare. Finally, at cytokinesis, SRcypdelmoca was located in the nucleus. The differences between the wild-type and deleted forms of SRcyp suggest that the moca domain fulfils important regulatory functions.
In Mitotic Cells, SRcyp Is Present in MIGs-During interphase, SRcyp is present in nuclear speckles (15) . These nuclear subdomains, which correspond to IGCs and perichromatin fibrils, contain many factors involved in the biogenesis of mRNAs (for a review see Ref. 23 ). Like SRcyp, many other components of the speckles are diffusely distributed in the cytoplasm at the start of mitosis and then begin to assemble into discrete structures around anaphase. These structures increase in number and size until late telophase, when they enter the nuclei of daughter cells. These mitotic structures are called MIGs because they have been shown to be morphologically similar to IGCs on electron microscopy (23). Turner and Franchi (35) have characterized a monoclonal antibody (mAb 3C5) that recognizes a group of phosphorylated SR proteins and stains both IGCs and MIGs. We checked that the observed cytoplasmic structures formed by SRcyp in mitotic cells corresponded to MIGs by means of indirect immunofluorescence experiments with anti-FLAG and 3C5 antibodies (see "Experimental Procedures"). Within telophasic cells, the cytoplasmic structures stained with the anti-FLAG antibody were also stained with the 3C5 antibody (Fig. 5D) . We Western-blotted cell extracts prepared from U2OS cells overproducing the SRcyp-FLAG protein to determine whether the observed colocal- 5) , each of which encompassed one of the Cdc2 phosphorylation sites (P1 to P5) identified in SRcyp. These peptides were used as substrates in a kinase assay carried out with the purified and active Cdc2-cyclin B complex. Pepc-, which contains the cAMP-dependent protein kinase phosphorylation site, was used as a negative control. For each sample, the substrate was incubated with and without the kinase, and the value presented in the figure corresponds to the radioactivity incorporated after subtraction of the background value obtained in the absence of kinase.
ization was due to specific recognition of the recombinant SRcyp protein by the 3C5 mAb; we found that this was not the case (data not shown). Thus, in mitotic cells, SRcyp is found in MIGs. containing multiple serine/arginine (S/R) dipeptide repeats (RS domains; for a review see Refs. 21 and 22) . Proteins bearing RS domains may be heavily phosphorylated by specific SR protein kinases (21, 22) . In addition, the presence of multiple consensus sites for many other kinases, such as CaMII, CKI, CKII, p70S6K, cAMP-dependent protein kinase, and protein kinase C and Cdc2, within the C-terminal tails of the cyclophilins of this group suggests that the function of these proteins may be regulated by phosphorylation in response to various signal transduction pathways and the cell cycle control machinery. Phosphorylation events may influence the cellular distribution of Moca cyclophilins and/or the interaction of these proteins with cellular partners and specific substrates. The study of such events is therefore of key importance and should provide insight into the function of this group of cyclophilins.
The Moca family member matrin-cyp has been shown to be a phosphoprotein (16) , but our report is the first to address in detail the issue of specific phosphorylation events targeting this group of cyclophilins. We focused on the nuclear cyclophilin SRcyp (14, 15) , a human protein belonging to the Moca family, and we demonstrated that the phosphorylation of this protein is regulated by the cell cycle. SRcyp is the first cell cycle-regulated cyclophilin to be described. The identification of five Cdc2-type phosphorylation sites concentrated in and around the moca domain of SRcyp suggested that the cell cycle might control the function of the protein via this highly conserved signature segment in the C-terminal tail of the cyclophilin. We demonstrated the specific phosphorylation of SRcyp and its CAD fragment in mitotic cells and the inhibitory effect of the cyclin-dependent kinase inhibitor roscovitine (33) . These findings suggested that the Cdc2-cyclin B complex, the master cyclin-dependent kinase active in mitotic cells (32) , was responsible for the observed mitosis-specific phosphorylation. The purified Cdc2-cyclin B kinase complex specifically phosphorylated the identified Cdc2-type phosphorylation sites in vitro, providing further evidence to support this possibility. The five sites were phosphorylated with different efficiencies, with the kinase preferentially phosphorylating the P2 site in the moca domain.
Clearly, there remain unanswered questions concerning the function of SRcyp and the reasons for which the moca domain must be phosphorylated by the Cdc2-cyclin B complex during mitosis. There is some evidence that SRcyp is involved in the regulation of gene expression. Indeed, the presence of RS domains within its C-terminal tail suggests that SRcyp may belong to the family of SR proteins, which are essentially involved in the regulation of pre-mRNA splicing (for reviews see Refs. 21 and 22) . However, SRcyp differs in several key points from prototypic SR proteins, which possess one or two N-terminal RNA recognition motifs (RRMs) followed by a C-terminal RS domain. First, although SRcyp has RNA binding activity, 3 no typical consensus RRM has been identified within its primary sequence. Second, the presence of N-terminal PPIase and C-terminal moca domains distinguishes SRcyp from typical SR proteins, suggesting that SRcyp has a specific, non-redundant function. Finally, unlike typical SR proteins, for which special purification procedures may be required (36, 37) , the recombinant SRcyp, overproduced in the human U2OS cell line, was extracted by a common procedure (see "Experimental Procedures"; data not shown). Thus, SRcyp does not seem to fit the strict definition of an SR protein, and it has not been experimentally proven to be an essential splicing factor. As SRcyp and certain other proteins carrying RS-like domains have been cloned through their interaction with the CTD of the largest subunit of RNA pol II (15, 38 -40) , they have also been named CTD-associated SR-like proteins (CASPs) (39) , and it has been suggested that they are involved in the elongation of transcription and/or the regulation of pre-mRNA splicing/maturation. As the elongating RNA pol II complex plays a key role in the coordination of transcription and pre-mRNA splicing (for a review see Ref. 41 ), CASPs may be involved in the fine-tuning of this coordination. The molecular function of CASPs is unknown. However, as RS domains are involved in protein-protein interactions (21) , it has been suggested that they may bind to other SR proteins via these domains and attract these proteins to the elongating RNA polymerase complex (39) . The PPIase activity of the cyclophilin SRcyp (15) could then target the hyperphosphorylated CTD of the largest subunit of RNA pol II itself or other SR proteins present in the complex. For the identification of SRcyp-associated proteins, we have set up CsA-affinity column conditions allowing the efficient binding of both the wild-type and moca domain-deleted forms of SRcyp. 4 The protein complexes, which will bind to the column via SRcyp, will be characterized by mass spectrometry. The comparison of wild-type and moca-deleted SRcyp columns should make it possible to identify moca domain-binding proteins.
During interphase, SRcyp, like many factors involved in the regulation of transcription and splicing of pre-mRNA, is found within nuclear speckles (15) . These electron-dense subnuclear domains, composed of IGCs and perichromatin fibrils, are thought to be implicated in the assembly and storage of factors involved in the transcription, splicing, and maturation of pre-mRNA and have been suggested to play a crucial role in the coordination of transcription with splicing (for a review see Ref. 23) . Speckles are assembled and disassembled during the course of the cell cycle. At the start of mitosis, when the nuclear envelope is disrupted and the general gene transcription and splicing machinery turned off (for reviews see Refs. 42 and 43), components of the speckles become dispersed in the cytoplasm. Later, around anaphase, many of these components form small condensed cytoplasmic structures, which increase in size and number as the cells pass from anaphase to telophase (44 -49) . These structures, which re-enter the nuclei around telophase, have been called MIGs, as ultrastructural studies have shown that they are equivalent to interphasic IGCs (48, 50, 51) . During mitosis, the recombinant SRcyp, overproduced in human U2OS cells, behaved like factors involved in the regulation of transcription and splicing of pre-mRNA. First, the protein was excluded from the chromosomes and was dispersed throughout the cytoplasm of the metaphasic cells. Subsequently, at anaphase, it passed through the MIGs and entered the newly formed nuclei at late telophase. The cell cycle-regulated movement of SRcyp seems to be conserved in other species as the mouse homolog of SRcyp also forms dense mitotic structures in the cytoplasm (16) . These structures have not been characterized in detail, but they probably correspond to MIGs.
The costaining of mitotic cells overproducing the recombinant SRcyp with anti-FLAG and anti-Lamin A/C antibodies showed that the cytoplasmic SRcyp-associated structures entered the nuclei of telophasic cells after the formation of the nuclear envelope. As SRcyp has a theoretical molecular mass of 88.6 kDa, it cannot diffuse in the nuclear compartment, and its import into the nucleus during late telophase probably requires mitosis-specific transport machinery. Prasanth et al. (49) recently demonstrated that the recruitment of individual factors involved in RNA pol II transcription and the pre-mRNA processing machinery in telophasic nuclei is nonrandom, sequential, and occurs after formation of the nuclear envelope. According to the model put forward by these authors, the time at which the components of the gene expression machinery appear and their availability in telophasic nuclei must be closely coordinated with the onset of transcription, and the differential release of factors from the cytoplasmic MIGs should play an important role in the regulation of this coordination. The presence of SRcyp in the MIGs suggests that this nuclear cyclophilin may be one of the key players in the reactivation of gene expression in post-mitotic cells.
During mitosis, the gene expression machinery is shut down, at least partly due to the phosphorylation, by the Cdc2-cyclin B complex, of a certain number of proteins involved in the regulation of this process (for a review see Ref. 42) . By analogy, phosphorylation by Cdc2-cyclin B might have an inhibitory effect on the unknown function of the moca domain during mitosis. However, we cannot exclude the possibility that additional kinases target the moca domain in a cell cycle-dependent manner. Indeed, one of the RS dipeptide repeats within the C-terminal tail of SRcyp is located in the middle of the moca domain, adjacent to the P2 Cdc2 phosphorylation site (see Fig. 1 ). This site was identified as that preferred by the Cdc2-cyclin B kinase complex in vitro. However, given the closeness of P2 to the RS repeat, which may be phosphorylated by specific RS kinases, there may be a cross-talk between the two phosphorylation pathways in vivo. In a yeast two-hybrid experiment, SRcyp was shown to form a complex with Clk/sty1, a nuclear SR domainspecific kinase (14, 21) . This kinase may phosphorylate the RS dipeptide repeats present in the moca domain or scattered throughout the rest of the C-terminal tail (see Fig. 1 ). Another SR domain-specific kinase, SRPK1, which seems to have mitotic activity (52) , may also phosphorylate SR repeats. However, as this enzyme was described as a cytoplasmic kinase (53), it may not act on SRcyp until this protein has been phosphorylated by the Cdc2-cyclin B complex and released into the cytoplasm.
Deletion of the moca domain of SRcyp disturbed many aspects of the mitotic movement of SRcyp in the stably transfected cells. Indeed, several major differences were observed with respect to the wild-type SRcyp. First, the presence of large aggregates of SRcyp-delmoca within the cytoplasm of prometaphasic cells suggested that the deleted fragment harbored an important regulatory element, conferring uniform dispersion in the cytoplasm. Second, anaphasic and telophasic cells harboring cytoplasmic MIGs were extremely rare in immunofluorescence experiments with SRcyp-delmoca. However, the presence of this rare cell population suggested that the passage of SRcyp through the MIGs was probably not totally dependent on the regulatory elements located within the deleted fragment. It is possible that the deletion of the moca domain may have disturbed certain aspects of the mitosis, affecting the number of telophasic cells. The loss of the SRcyp-delmoca protein from a fraction of the cell population, together with the apoptotic character of the cell line, is consistent with this hypothesis. In the future, more detailed mutational analysis of the moca domain and of the identified phosphorylation sites, together with time-lapse analysis in living cells, should make it possible to determine the precise role of phosphorylation by Cdc2-cyclin B kinase in the regulation of SRcyp during the course of mitosis.
